A high-throughput drug screen reveals means to differentiate triple-negative breast cancer. Vulin M, Jehanno C, Sethi A, Correia AL, et al. Oncogene 2022 Aug 25. pii: 10.1038/s41388-022-02429.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Vulin M, Jehanno C, Sethi A, Correia AL, et al. A high-throughput drug screen reveals means to differentiate triple-negative breast cancer. Oncogene 2022 Aug 25. pii: 10.1038/s41388-022-02429.
PMID: 36008466